Why choose Orthoregentec?
Innovative Hydrogel Platform
targeted, sustained drug delivery
Research-Driven
backed by The Hong Kong Polytechnic University
Patient-Centered
designed for long-lasting relief with fewer treatments
Challenges in the Treatment of Osteoarthritis
Osteoarthritis causes cartilage degeneration, chronic pain, and reduced mobility. Current treatments focus only on symptom relief, leaving a huge unmet need for disease-modifying solutions.
Our Approach
Our hydrogel platform enables controlled, long-term release of therapeutic agents to the joint, aiming to slow disease progression and regenerate cartilage while reducing the need for repeat procedures.
Evidence So Far：
-
Discovered key link between OA pathology and cellular senescence
-
Developed AAVs targeting Sirt7 to slow joint aging
-
Verified early efficacy in laboratory studies
Market Validation
Our hydrogel aligns with patient needs and supports clinicians by reducing repeat visits.
Survey of 243 OA patients in Hong Kong
70% interested in convenient, long-lasting treatments.
Top concerns
affordability, safety, and effectiveness.
Our Team
Prof. WEN Chunyi
Associate Professor, Biomedical Engineering, The Hong Kong Polytechnic University (Lab’s Page)
Dr. NI Junguo
Postdoctoral Fellow, Biomedical Engineering, The Hong Kong Polytechnic University
LI Zhan
PhD Candidate, Biomedical Engineering, The Hong Kong Polytechnic University